

We are recruiting participants for the Lullaby-002 Study



Effective and safe varicella vaccines have demonstrated significant impact in national immunization programs worldwide. New varicella vaccines may offer additional public health advantages to prevent varicella.

The Lullaby-002 Study is a Phase 3a, observer-blind, randomized, controlled study of a new investigational varicella vaccine. The Lullaby-002 Study will evaluate the immunogenicity, safety, and reactogenicity of the investigational varicella vaccine compared with *Varivax*® when co-administered with other age-appropriate vaccines. The study will include about 1840 healthy children worldwide, with participation lasting for up to 6 months.

Participation involves 3 study visits, up to 2 of which can be phone calls. Participants will receive:

- 1 dose of either the investigational varicella vaccine or the *Varivax*® vaccine
- 1 dose of approved vaccines against:
 - measles, mumps, and rubella
 - hepatitis A
 - *Streptococcus pneumoniae* bacteria, if the participant is in a country where a pneumococcal conjugate vaccine (PCV) is recommended at 12–15 months of age and provided as part of this study.

We are looking for healthy children 12–15 months of age who:

- ✓ do not have a history of receiving a varicella vaccine or having varicella disease
- ✓ received the primary series of PCV in the first year of life at least 60 days prior to the study (applicable in countries where PCV is recommended at 12–15 months of age per national immunization program and provided as part of this study).

We are not looking for children who:

- ✗ were previously vaccinated against measles, mumps, and rubella, and hepatitis A
- ✗ are participating in another clinical research study.

Additional requirements apply.

We would be very grateful if you would consider referring children (with their parents'/legally authorized representatives' permission) who may be eligible for the Lullaby-002 Study.

Diversity among our clinical study participants is important to assess risk/benefit ratios for different groups. We request your help in considering the referral of children who reflect the population at risk of varicella disease.

Enrolling Now!

402-937-9392

bewellclinicalstudies.com



Lullaby-002 Study Team



You can also visit Lullabychickenpoxprogram.com or scan this QR code to learn more:

